Studies show promise for 2 new COVID vaccine platforms.

Commentary: Studies show promise for 2 new COVID vaccine platforms – CIDRAP

Study 1: Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine – New England Journal of Medicine

Study 2: Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults – New England Journal of Medicine

Editorial: Does the World Still Need New Covid-19 Vaccines?

Commentaries on Twitter

Efficacy of a plant-based vaccine with adjuvant was 69.5% against symptomatic #COVID19 and 78.8% against moderate-to-severe disease. https://t.co/WH54QWCBdg pic.twitter.com/BiEYpJUD7D

— NEJM (@NEJM) May 4, 2022

ZF2001 vaccine has 87% efficacy against critical or severe #COVID19 for at least 6 months after full vaccination and was safe in large cohort of adults. #IDTwitter https://t.co/wsG0AXqI4Y pic.twitter.com/45fqwVrz9a

— NEJM (@NEJM) May 4, 2022